Invesaro

Stocks Health care VREOF

OTC · Health care

Vireo Growth Inc. (VREOF)

Vireo Growth Inc. brought in $511.7M of revenue over the twelve months to June 30, 2026, up 316.7% from a year earlier. It posted a net loss of $67.1M. In fiscal 2025 capital spending exceeded operating cash flow by $24.6M. At June 30, 2026 it held $122.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch VREOF in 60 seconds
Price
$10.71
-4.20% on the day · September 28, 2026
52-week range $8.91 to $22.50
Revenue (last 12 months)
$511.7M
+316.7% year on year
Net margin
-13.1%

What Vireo Growth Inc. does

Vireo Growth Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker VREOF.

Revenue and profit by year

Revenue
FY21: $49.2M $49.2M FY21FY21: $54.4M $54.4M FY21FY22: $74.6M $74.6M FY22FY23: $88.1M $88.1M FY23FY24: $99.4M $99.4M FY24FY25: $268.8M $268.8M FY25
Net income
FY21: -$22.9M -$22.9M FY21FY21: -$33.7M -$33.7M FY21FY22: -$42.5M -$42.5M FY22FY23: -$25.5M -$25.5M FY23FY24: -$28M -$28M FY24FY25: -$68.1M -$68.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$268.8M-$1M-$68.1M-$0.09-$24.6M
2024$99.4M$13.6M-$28M-$0.16-$21.9M
2023$88.1M$10.6M-$25.5M-$0.19-$5.9M
2022$74.6M-$6.9M-$42.5M-$0.33-$23.6M
2021$54.4M-$20.5M-$33.7M-$0.27-$48.6M
2021$49.2M-$23M-$22.9M-$0.24-$19.4M

Full financial statements: income, balance sheet and cash flow

Next report expected around October 9, 2026.

Estimated from its filing rhythm: about 60 days after its last report of August 11, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where VREOF ranks in Health care

Revenue$268.8M
#247 of 742 in Health care · Top 33%
Revenue growth+170.4%
#34 of 529 in Health care · Top 6%
Net margin-25.3%
#340 of 541 in Health care · Bottom 37%
Free cash flow margin-9.2%
#290 of 488 in Health care · Bottom 41%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Vireo Growth Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 28, 2026
  2. August 26, 2026
  3. August 26, 2026
  4. August 25, 2026
  5. August 18, 2026
  6. August 18, 2026
  7. August 18, 2026
  8. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue rose 335% to $209.3M versus the same quarter last year; diluted EPS $0.00 versus -$0.80.
  9. August 13, 2026
  10. August 13, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 8, 2026. Insider transactions on SEC

Insider trades

What the people running Vireo Growth Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
May 15, 2026 Apfelbaum Sean MichaelGC and Corporate Secretary Exercised options 133,333 - - Form 4
May 15, 2026 Apfelbaum Sean MichaelGC and Corporate Secretary Shares withheld for tax 39,067 $0.39 $15K Form 4
May 15, 2026 Duxbury JosephChief Accounting Officer Exercised options 133,333 - - Form 4
May 15, 2026 Duxbury JosephChief Accounting Officer Shares withheld for tax 40,799 $0.39 $15.7K Form 4
December 29, 2025 Apfelbaum Sean MichaelGC and Corporate Secretary Shares withheld for tax 62,145 $0.64 $39.8K Form 4
December 29, 2025 Kingsley Kyle EugeneCo-Executive Chairman, Director Shares withheld for tax 276,509 $0.60 $165.9K Form 4
December 29, 2025 Kingsley Kyle EugeneCo-Executive Chairman, Director Shares withheld for tax 1,425,171 $0.67 $954.9K Form 4
December 29, 2025 Shimpa Amber HollyPresident Shares withheld for tax 126,666 $0.60 $76K Form 4
September 30, 2025 Apfelbaum Sean MichaelGC and Corporate Secretary Exercised options 200,000 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns VREOF

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 14,366,667 shares in total, about $153.9M at the last price.

HolderSharesAs of
Kingsley Kyle EugeneCo-Executive Chairman, Director 12,781,192 December 29, 2025
Shimpa Amber HollyPresident 1,119,965 December 29, 2025
Apfelbaum Sean MichaelGC and Corporate Secretary 369,976 May 15, 2026
Duxbury JosephChief Accounting Officer 95,534 May 15, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about VREOF

What does Vireo Growth Inc. do?

Vireo Growth Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker VREOF.

Is Vireo Growth Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $67.1M on revenue of $511.7M.

How much revenue does Vireo Growth Inc. make?

Over the twelve months to June 30, 2026 Vireo Growth Inc. reported revenue of $511.7M. That is 316.7% more than a year earlier.

When did Vireo Growth Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form 425 filing from August 28, 2026.

Similar companies

Compare VREOF with

Compare VREOF with any company

Follow VREOF

Get an email when Vireo Growth Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow VREOF: get an email when it files

Where the numbers come from

Financial figures are the values Vireo Growth Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.